Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications

NAActive, not recruitingINTERVENTIONAL
Enrollment

5,269

Participants

Timeline

Start Date

October 1, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

February 28, 2025

Conditions
Myocardial IschemiaRheumatic Diseases
Interventions
OTHER

Caplan IVR

This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.

Trial Locations (5)

21201

Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore

27705

Durham VA Medical Center, Durham, NC, Durham

94121

San Francisco VA Medical Center, San Francisco, CA, San Francisco

80045-7211

Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora

00921

VA Caribbean Healthcare System, San Juan, PR, San Juan

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT02694185 - Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications | Biotech Hunter | Biotech Hunter